Table 2.
Surveillance strategy with opportunistic AF-screening
| Study | Size | AF-screening | Device (n) | AF < 1 m | AF ≥ 1 m |
|---|---|---|---|---|---|
| Alaeddini et al. (2006) [24] | 71 | ECG 1, 6, 12 m; symptoms Holter | CardioSEAL (67), Amplatzer PFO (4) | 2 (2.8%) | 1 (1.4%) |
| Kiblawi et al. (2006) [25] | 456 | ECG 1, 6 m; symptoms Holter | CardioSEAL (456) | 16 (3.5%) | 0 |
| Staubach et al. (2009) [5] | 1349 | ECG 1, 3, 6 m, yearly; symptoms ECG/Holter | Amplatzer (535), Helex (379), Starflex (270), Premere (131), Sideris (9), Asdos (9), CardioSEAL (7), Angelwings (5), PFO Star (4) | 33 (2.4%) | 20 (1.5%) |
| Wagdi (2010) [6] | 68 | ECG 1, 6 m; symptoms Holter | Amplatzer (28), Occlutech (20), Solysafe (9), Premere (8), Cardia (3) | 1 (1.8%) | 7 (10.3%) |
| Bronzetti et al. (2011) [26] | 276 | ECG 1, 6, 12 m, yearly; symptoms ECG/Holter | Amplatzer PFO (174), CardioSEAL (57), Premere (28), Helex (7), Cardia (5), Biostar (5) | 10 (3.6%) | 1 (0.4%) |
| Hornung et al. (2013) [27] | 660 | ECG 1, 6 m; symptoms ECG/Holter | Amplatzer PFO (220), CardioSEAL (220), Helex (220) | 18 (2.7%) | 22 (3.3%) |
| Geis et al. (2015) [29] | 41 | ECG 6 w, 6 m, Holter symptoms | Cardioform Septal (41) | 0 | 2 (4.9%) |
| Rigatelli et al. (2016) [8] | 1000 | ECG 1, 6, 12 m, yearly; Holter 1 m | Amplatzer PFO (463), Amplatzer Cribiform (420), Premere (95), Biostar (22) | 47 (4.7%) | 5 (0.5%) |
| He et al. (2020) [28] | 268 | ECG 1, 3, 6, 12 m; Holter 1 m + symptoms | Amplatzer PFO (268) | 1 (0.4%) | 1 (0.4%) |
| Andersen et al. (2021) [10] | 664 | Holter; ECG 1, 6, 12, 24 m | Helex (158), Cardioform Septal (250) | 27 (6.6%) | 7 (1.7%) |
A amplatzer, AF atrial fibrillation, B biostar, CS CardioSEAL, DU device unclear, H helex, m month, O occlutech, P premere, Si sideris, So solysafe, St starflex